Dong-Ho Song

Dong-Ho Song

Auto-generated profile, based on publicly available information

Dong-Ho Song

Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Cell
Verified
Journal Article
Closed access
PLPhil H. Lee
Phil H. Lee
VAVerneri Anttila
Verneri Anttila
HWHyejung Won
Hyejung Won
YFYen-Chen A. Feng
Yen-Chen A. Feng
JRJacob Rosenthal
Jacob Rosenthal
JSJordan Smoller
Jordan Smoller

1 September 2011 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
YKYoung Shin Kim
Young Shin Kim
BLBennett L. Leventhal
Bennett L. Leventhal
YKYun-Joo Koh
Yun-Joo Koh
EFEric Fombonne
Eric Fombonne
ELEugene Laska
Eugene Laska
RGRoy Richard Grinker
Roy Richard Grinker

1 October 2001 in Biological Psychiatry
Verified
Journal Article
Closed access
MGMarco Grados
Marco Grados
MRMark A Riddle
Mark A Riddle
JSJack F Samuels
Jack F Samuels
KLKung-Yee Liang
Kung-Yee Liang
RHRudolf Hoehn-Saric
Rudolf Hoehn-Saric
GNGerald Nestadt
Gerald Nestadt

1 September 2018 in Cell Reports
Verified
Journal Article
Open access
SWSheng Wang
Sheng Wang
JMJeffrey D. Mandell
Jeffrey D. Mandell
YKYogesh Kumar
Yogesh Kumar
NSNawei Sun
Nawei Sun
MMMontana T. Morris
Montana T. Morris
AWA. Jeremy Willsey
A. Jeremy Willsey
We previously established the contribution of de novo damaging sequence variants to Tourette disorder (TD) through whole-exome sequencing of 511 trios. Here, we sequence an additional 291 TD trios and analyze the combined set of 802 trios. We observe an overrepresentation of de novo damaging variants in simplex, but not multiplex, families; we identify a high-confidence TD risk gene, CELSR3 (cadherin EGF LAG seven-pass G-type receptor 3); we find that the genes mutated in TD patients are enriched for those related to cell polarity, suggesting a common pathway underlying pathobiology; and we confirm a statistically significant excess of de novo copy number variants in TD. Finally, we identify significant overlap of de novo sequence variants between TD and obsessive-compulsive disorder and de novo copy number variants between TD and autism spectrum disorder, consistent with shared genetic risk.

1 March 2007 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
YWYufeng Wang
Yufeng Wang
YZYi Zheng
Yi Zheng
YDYasong Du
Yasong Du
DSDong H. Song
Dong H. Song
YSYee-Jin Shin
Yee-Jin Shin
LLLouise R. Levine
Louise R. Levine
Objective: To (i) test whether atomoxetine is non-inferior to methylphenidate in treating symptoms of attention deficit hyperactivity disorder (ADHD) in paediatric patients; and (ii) determine the tolerability of the two drugs. Method: This double-blind study was conducted in 6- to 16-year-old outpatients with ADHD (DSM-IV) in China, Korea and Mexico (January–October 2004). Patients were randomly assigned to once-daily atomoxetine (0.8–1.8 mg kg −1 day −1 ; n = 164) or twice-daily methylphenidate (0.2–0.6 mg kg −1 day −1 ; n = 166) for ∼8 weeks. Primary efficacy assessment was the comparison of response rates (≥40% reduction from baseline to end point in total score) on the Attention Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and -Scored. Tolerability measures included, but were not limited to, the assessment of treatment-emergent adverse events (TEAEs) and weight. Results: Atomoxetine was non-inferior to methylphenidate in improving ADHD symptoms based on response rates (atomoxetine, 77.4%; methylphenidate, 81.5%; one-sided 95% lower confidence limit = −11.7%, p = 0.404). Treatment-emergent adverse effects experienced significantly more frequently in the atomoxetine group, compared with the methylphenidate group, included anorexia (37.2% vs. 25.3%; p = 0.024), nausea (20.1% vs. 10.2%; p = 0.014), somnolence (26.2% vs. 3.6%; p <0.001), dizziness (15.2% vs. 7.2%; p = 0.024) and vomiting (11.6% vs. 3.6%; p = 0.007), most of which were of mild or moderate severity. Atomoxetine-treated patients experienced a small but significantly greater mean weight loss from baseline to end point than methylphenidate-treated patients (−1.2 kg vs. −0.4 kg; p <0.001). Conclusions: This study suggests that atomoxetine is non-inferior to methylphenidate in the improvement of ADHD symptoms in paediatric outpatients. Although both of the drugs were well tolerated, atomoxetine was associated with a higher incidence of TEAEs than methylphenidate.

1 January 2014 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
KSKyeong In Seol
Kyeong In Seol
SSSeung Ha Song
Seung Ha Song
KKKa Lim Kim
Ka Lim Kim
SOSeung Taek Oh
Seung Taek Oh
YKYoung Tae Kim
Young Tae Kim
KCKeun-Ah Cheon
Keun-Ah Cheon
Seol KI, et al. Yonsei Med J. 2014 Nov;55(6):1721-1728. https://doi.org/10.3349/ymj.2014.55.6.1721